110 related articles for article (PubMed ID: 20444435)
1. Methylxanthine reversal of opioid-evoked inspiratory depression via phosphodiesterase-4 blockade.
Ruangkittisakul A; Ballanyi K
Respir Physiol Neurobiol; 2010 Jul; 172(3):94-105. PubMed ID: 20444435
[TBL] [Abstract][Full Text] [Related]
2. Methylxanthines do not affect rhythmogenic preBötC inspiratory network activity but impair bursting of preBötC-driven motoneurons.
Panaitescu B; Kuribayashi J; Ruangkittisakul A; Leung V; Iizuka M; Ballanyi K
Neuroscience; 2013; 255():158-76. PubMed ID: 24120555
[TBL] [Abstract][Full Text] [Related]
3. Reversal by phosphodiesterase-4 blockers of in vitro apnea in the isolated brainstem-spinal cord preparation from newborn rats.
Ruangkittisakul A; Ballanyi K
Neurosci Lett; 2006 Jun; 401(1-2):194-8. PubMed ID: 16581183
[TBL] [Abstract][Full Text] [Related]
4. Methylxanthine-evoked perturbation of spontaneous and evoked activities in isolated newborn rat hippocampal networks.
Ruangkittisakul A; Sharopov S; Kantor C; Kuribayashi J; Mildenberger E; Luhmann HJ; Kilb W; Ballanyi K
Neuroscience; 2015 Aug; 301():106-20. PubMed ID: 26047722
[TBL] [Abstract][Full Text] [Related]
5. Silencing by raised extracellular Ca2+ of pre-Bötzinger complex neurons in newborn rat brainstem slices without change of membrane potential or input resistance.
Panaitescu B; Ruangkittisakul A; Ballanyi K
Neurosci Lett; 2009 May; 456(1):25-9. PubMed ID: 19429127
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
7. cAMP-dependent reversal of opioid- and prostaglandin-mediated depression of the isolated respiratory network in newborn rats.
Ballanyi K; Lalley PM; Hoch B; Richter DW
J Physiol; 1997 Oct; 504 ( Pt 1)(Pt 1):127-34. PubMed ID: 9350624
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
9. G protein activation in rat ponto-mesencephalic nuclei is enhanced by combined treatment with a mu opioid and an adenosine A1 receptor agonist.
Tanase D; Martin WA; Baghdoyan HA; Lydic R
Sleep; 2001 Feb; 24(1):52-62. PubMed ID: 11204054
[TBL] [Abstract][Full Text] [Related]
10. Activation of opioid mu receptors in caudal medullary raphe region inhibits the ventilatory response to hypercapnia in anesthetized rats.
Zhang Z; Xu F; Zhang C; Liang X
Anesthesiology; 2007 Aug; 107(2):288-97. PubMed ID: 17667574
[TBL] [Abstract][Full Text] [Related]
11. Blockade of phosphodiesterase 4 reverses morphine-induced ventilatory disturbance without loss of analgesia.
Kimura S; Ohi Y; Haji A
Life Sci; 2015 Apr; 127():32-8. PubMed ID: 25744400
[TBL] [Abstract][Full Text] [Related]
12. Respiratory effects of xanthines and adenosine analogs in rhesus monkeys.
Howell LL; Morse WH; Spealman RD
J Pharmacol Exp Ther; 1990 Sep; 254(3):786-91. PubMed ID: 2395111
[TBL] [Abstract][Full Text] [Related]
13. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
14. Glial TLR4 signaling does not contribute to opioid-induced depression of respiration.
Zwicker JD; Zhang Y; Ren J; Hutchinson MR; Rice KC; Watkins LR; Greer JJ; Funk GD
J Appl Physiol (1985); 2014 Oct; 117(8):857-68. PubMed ID: 25103966
[TBL] [Abstract][Full Text] [Related]
15. Depression of C fibre-evoked spinal field potentials by the spinal delta opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: involvement of the mu-subtype.
Buesa I; Urrutia A; Aira Z; Salgueiro M; Bilbao J; Mozas M; Aguilera L; Zimmermann M; Azkue JJ
Neuropharmacology; 2008 Dec; 55(8):1376-82. PubMed ID: 18775732
[TBL] [Abstract][Full Text] [Related]
16. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes.
Ukena D; Schudt C; Sybrecht GW
Biochem Pharmacol; 1993 Feb; 45(4):847-51. PubMed ID: 7680859
[TBL] [Abstract][Full Text] [Related]
17. Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: mechanism and location of action.
Mosca EV; Ciechanski P; Roy A; Scheibli EC; Ballanyi K; Wilson RJ
Respir Physiol Neurobiol; 2014 Aug; 200():80-9. PubMed ID: 24914466
[TBL] [Abstract][Full Text] [Related]
18. A μ-opioid receptor agonist DAMGO induces rapid breathing in the arterially perfused in situ preparation of rat.
Koganezawa T; Okada Y; Terui N; Paton JF; Oku Y
Respir Physiol Neurobiol; 2011 Jul; 177(2):207-11. PubMed ID: 21513819
[TBL] [Abstract][Full Text] [Related]
19. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
Cahill CM; White TD; Sawynok J
J Pharmacol Exp Ther; 1995 Oct; 275(1):84-93. PubMed ID: 7562600
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of mu-opioid receptor agonists in a hippocampal hypoxia/hypoglycemia model.
Ammon-Treiber S; Stolze D; Höllt V
Brain Res; 2007 Dec; 1183():60-5. PubMed ID: 17936735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
